Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Stock Price
RXRXStock
$3.34−31.35%52W
Market Cap$1.79B
P/E—
PEG Ratio—
Div yield—
Beta1.09
RXRX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-17.31%
Price vs S&P 500 (4W)3.49%
VGM Score43.77
RXRX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.23 | -$0.25 | -6.84%(-$0.02) | |
| Q1 2026 | -$0.26 | -$0.22 | +14.44%(+$0.04) | |
| Q4 2025 | -$0.32 | -$0.21 | +33.34%(+$0.11) | |
| Q3 2025 | -$0.38 | -$0.36 | +5.68%(+$0.02) | |
| Q2 2025 | -$0.35 | -$0.41 | -16.04%(-$0.06) |
RXRX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
3.71
3.71
3.71
3.77
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock | D | C | C | $3.34 |
| AMGNAmgen Inc | C | C | B | $432.42 |
| GILDGilead Sciences Inc | C | B | B | $145.68 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1023.21 |
| MRNAModerna, Inc. Common Stock | D | C | A | $137.99 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $207.88 |
| BIIBBiogen Inc. Common Stock | C | D | B | $218.50 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $102.08 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $154.06 |
| EXELExelixis Inc | C | B | B | $54.45 |
| HALOHalozyme Therapeutics, Inc. | C | B | B | $105.35 |
About Recursion Pharmaceuticals, Inc. Class A Common Stock
Recursion Pharmaceuticals is a clinical-stage biotech company that integrates computational and experimental technologies—including chemistry, automation, and data science—to accelerate drug discovery and industrialize development. The platform aims to decode biological processes and de-risk the path from research to therapeutic approval. U.S. operations represent the company's primary revenue source, with additional presence in the United Kingdom and other markets.